Literature DB >> 2167668

1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles.

E Hasegawa1, K Takeshige, T Oishi, Y Murai, S Minakami.   

Abstract

We studied the effects of 1-methyl-4-phenylpyridinium (MPP+), a metabolite of a parkinsonism-inducing drug, on the superoxide formation and the lipid peroxidation in bovine heart submitochondrial particles. The NADH-supported formation of superoxide radicals was induced by MPP+ at the concentration which is considered to exist in mitochondria of dopamine neurons. The formation increased as the NADH-ubiquinone reductase activity was inhibited by MPP+. The NADH-supported lipid peroxidation by the particles in the presence of ADP-Fe3+ chelate was also enhanced by MPP+ at similar concentrations. The formation was inhibited by succinate and the reduction of endogenous ubiquinone seems to be related to the inhibition. A possibility was discussed that the formation of superoxide anions and the lipid peroxidation may contribute in the cytotoxicity of the drug.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2167668     DOI: 10.1016/0006-291x(90)90498-c

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  80 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons.

Authors:  Hui-Ming Gao; Jau-Shyong Hong; Wanqin Zhang; Bin Liu
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

3.  NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  Du-Chu Wu; Peter Teismann; Kim Tieu; Miquel Vila; Vernice Jackson-Lewis; Harry Ischiropoulos; Serge Przedborski
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-29       Impact factor: 11.205

Review 4.  MPTP as a mitochondrial neurotoxic model of Parkinson's disease.

Authors:  Serge Przedborski; Kim Tieu; Celine Perier; Miquel Vila
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

5.  Chronic dichlorvos exposure: microglial activation, proinflammatory cytokines and damage to nigrostriatal dopaminergic system.

Authors:  B K Binukumar; Amanjit Bal; Kiran Dip Gill
Journal:  Neuromolecular Med       Date:  2011-10-04       Impact factor: 3.843

6.  Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.

Authors:  Hironori Yokoyama; Ryohei Yano; Hayato Kuroiwa; Tatsuya Tsukada; Hiroto Uchida; Hiroyuki Kato; Jiro Kasahara; Tsutomu Araki
Journal:  Metab Brain Dis       Date:  2010-04-28       Impact factor: 3.584

7.  Unregulated mitochondrial GSK3beta activity results in NADH: ubiquinone oxidoreductase deficiency.

Authors:  Taj D King; Buffie Clodfelder-Miller; Keri A Barksdale; Gautam N Bijur
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

Review 8.  Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Authors:  Chun Zhou; Yong Huang; Serge Przedborski
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

9.  Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains.

Authors:  Jason Callio; Tim D Oury; Charleen T Chu
Journal:  J Biol Chem       Date:  2005-03-08       Impact factor: 5.157

10.  Norharman-induced motoric impairment in mice: neurodegeneration and glial activation in substantia nigra.

Authors:  A Ostergren; A Fredriksson; E B Brittebo
Journal:  J Neural Transm (Vienna)       Date:  2005-08-03       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.